PharmaCyte Biotech EBIT per Share
The EBIT per Share of PharmaCyte Biotech (PMCB) as of Oct 22, 2026 is -0.64 USD. In the previous year, EBIT per Share was -0.64 USD — a change of -0.90% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.64USD
YoY
-0.90%
Last updated:
The PharmaCyte Biotech EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| -0.64USD | -0.90% | |
| -0.64USD | -42.26% | |
| -1.12USD | +51.48% | |
| -0.74USD | +245.20% | |
| -0.21USD | +2.22% | |
| -0.21USD | -91.60% | |
| -2.49USD | -46.46% | |
| -4.64USD | -52.09% | |
| -9.69USD | +41.52% | |
| -6.85USD | -36.19% | |
| -10.73USD | -61.07% | |
| -27.56USD | -31.91% | |
| -40.48USD | +767.01% | |
| -4.67USD | -99.93% | |
| -6,497.27USD | +417,313.11% | |
| -1.56USD | -82.85% | |
| -9.07USD | -72.45% | |
| -32.94USD | +27.85% | |
| -25.77USD | -21.93% | |
| -33.01USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PharmaCyte Biotech Stock analysis
Frequently Asked Questions about PharmaCyte Biotech stock
EBIT per Share of PharmaCyte Biotech is -0.64 USD in 2026.
EBIT per Share of PharmaCyte Biotech changed from -0.64 USD to -0.64 USD, representing a -0.90% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share PharmaCyte Biotech since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — PharmaCyte Biotech
All Key Metrics — PharmaCyte Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth